Get started
Author

Sjoerd H. Hofma

Observed names: S H Hofma, S Hofma, S. H. Hofma, S.H Hofma, S.H. Hofma, SJOERD H. HOFMA, Sjoerd H Hofma, Sjoerd Hofma, Sjoerd Hofma Hofma, Sjoerd. H. Hofma
Observed institutions: Sahlgrenska University Hospital, Erasmus MC, Medisch Centrum Leeuwarden, Amsterdam UMC Location University of Amsterdam, Yale University, OLVG, Tergooi, Amsterdam University Medical Centers, Frisius MC, Sapienza University of Rome, University of Amsterdam, Erasmus University Rotterdam
OpenAlex ID: A5048845661
2018 ESC/EACTS Guidelines on myocardial revascularization
2018 · Franz-Josef Neumann, Miguel Sousa-Uva, et al. · European Heart Journal · 7,159
PDF
2018 ESC/EACTS Guidelines on myocardial revascularization
2018 · Miguel Sousa-Uva, Franz-Josef Neumann, et al. · European Journal of Cardio-Thoracic Surgery · 991
PDF
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
2018 · Pascal Vranckx, Marco Valgimigli, et al. · The Lancet · 791
PDF
Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
2010 · Patrick W. Serruys, Sigmund Silber, et al. · New England Journal of Medicine · 670
PDF
Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”
2003 · Pedro A. Lemos, Patrick W. Serruys, et al. · Circulation · 543
PDF
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI
2017 · Joanna J. Wykrzykowska, Robin P. Kraak, et al. · New England Journal of Medicine · 442
PDF
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation
2005 · Sjoerd H. Hofma, Wim J. van der Giessen, et al. · European Heart Journal · 384
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial
2020 · Marieke Gimbel, Khalid Qaderdan, et al. · The Lancet · 357
PDF
Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients
2004 · Pedro A. Lemos, Angela Hoye, et al. · Circulation · 333
PDF
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial
2013 · Pieter Cornelis Smits, Sjoerd Hofma, et al. · The Lancet · 293
Coronary Restenosis After Sirolimus-Eluting Stent Implantation
2003 · Pedro A. Lemos, Francesco Saia, et al. · Circulation · 286
PDF
Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial
2015 · Manel Sabaté, Stephan Windecker, et al. · European Heart Journal · 218
PDF
Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions
2004 · Angela Hoye, Kengo Tanabe, et al. · Journal of the American College of Cardiology · 217
Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction
2004 · Pedro A Lemos, Francesco Saia, et al. · Journal of the American College of Cardiology · 208
Stent fracture and restenosis in the drug‐eluting stent era
2003 · Georgios Sianos, Sjoerd Hofma, et al. · Catheterization and Cardiovascular Interventions · 200
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients
2022 · Nicolas M. Van Mieghem, G. Michael Deeb, et al. · JAMA Cardiology · 194
Reduction in Thrombotic Events With Heparin-Coated Palmaz-Schatz Stents in Normal Porcine Coronary Arteries
1996 · Peter A. Hårdhammar, Heleen M.M. van Beusekom, et al. · Circulation · 187
Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries
1998 · Heleen M.M. van Beusekom, Deirdre M. Whelan, et al. · Journal of the American College of Cardiology · 168
PDF
Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings
2004 · Kengo Tanabe, Angela Hoye, et al. · The American Journal of Cardiology · 159
Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus-Eluting Stents in Acute Myocardial Infarction
2012 · Sjoerd H. Hofma, Jan Brouwer, et al. · Journal of the American College of Cardiology · 128
PDF
Outcome After ST Elevation Myocardial Infarction in Patients With Cancer Treated With Primary Percutaneous Coronary Intervention
2013 · Matthijs A. Velders, Helèn Boden, et al. · The American Journal of Cardiology · 123
Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction
2003 · Francesco Saia, Pedro A. Lemos, et al. · Circulation · 115
PDF
The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents
2011 · Giulio G. Stefanini, Patrick W. Serruys, et al. · Journal of the American College of Cardiology · 113
The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents
2011 · Scot Garg, Patrick W. Serruys, et al. · JACC: Cardiovascular Interventions · 107
PDF
Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease
2017 · Georgios J. Vlachojannis, Pieter C. Smits, et al. · JACC: Cardiovascular Interventions · 102
PDF
Works count: 143
Citation count: 16,020
H-index: 37
I10-index: 66
Year
Topic
Type